Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· November 27, 2025

BioNTech (BNTX) Q3 2025 Earnings Call Transcript

BioNTech (BNTX) Q3 2025 Earnings Call Transcript Image source: The Motley Fool. Date Nov. 3, 2025 at 12:46 p.m…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

BioNTech is positioned as a fully integrated AI-tech bio company with AI capabilities addressing inter-patient heterogeneity and intra-tumor variability
80% confidence
We expect to report a loss for the 2025 financial year as we continue to invest in our transition to become a fully integrated commercial oncology company
80% confidence
T-cell response breadth correlates with activity in iNeST therapy; immune cell PD-L1 matters; signal observed in TMB-low patients
80% confidence
First pivotal combination regimen decisions for Pumitamig expected based on data over next year
80% confidence
Management emphasized rigorous financial discipline and focus on long-term sustainable growth
80% confidence
First potential launches of Pumitamig expected before end of decade (pre-2030)
80% confidence
COVID-19 vaccine business has stable market share and pricing with lower volumes vs prior year, performing within expectations
80% confidence
US COVID-19 vaccination rate at ~20% is in line with expectations
80% confidence